4th death, more vision loss cases linked to tainted eyedrops

By AP News


U.S. health officials are reporting another death and several more cases of vision loss linked to eyedrops tainted with a drug-resistant bacteria

Eyedrops Recall

NEW YORK (AP) — U.S. health officials reported another death and several more cases of vision loss from illnesses linked to eyedrops tainted with a drug-resistant bacteria.

The bacteria has infected 81 people, including four who died and 14 who lost vision, the Centers for Disease Control and Prevention said Friday. That’s up from three deaths and eight cases of vision loss reported in March. The CDC also said four people have undergone surgery to remove an eyeball due to the infections.

The outbreak is considered particularly worrisome because the bacteria driving it — Pseudomonas aeruginosa — is resistant to standard antibiotics.

Investigators say most of the patients had used certain brands of eyedrops, and products from EzriCare and Delsam Pharma were recalled in February. At least seven patients were diagnosed after the recall.

After the recall, U.S. health inspectors visited the plant in India that made the eyedrops and uncovered problems with how the drops were made and tested, including inadequate sterility measures.

Cases have been reported from 18 states — California, Colorado, Connecticut, Delaware, Florida, Illinois, North Carolina, New Jersey, New Mexico, Nevada, New York, Ohio, Pennsylvania, South Dakota, Texas, Utah, Washington and Wisconsin.


The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.


Author: AP News

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Originally published by Associated Press Valuethemarkets.com, Digitonic Ltd (and our owners, directors, officers, managers, employees, affiliates, agents and assigns) are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above.

Sign up for Investing Intel Newsletter